Cargando…
Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation
Langerhans cell histiocytosis (LCH) is an infrequent disease, characterized by oligoclonal proliferation of immature myeloid-derived cells. However, the exact pathogenesis remains unknown. In rare cases, LCH is present in patients with concomitant myeloid proliferative neoplasms. Here, we describe a...
Autores principales: | Holst, Johanne Marie, Enemark, Marie Beck, Plesner, Trine Lindhardt, Pedersen, Martin Bjerregaard, Ludvigsen, Maja, d'Amore, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068553/ https://www.ncbi.nlm.nih.gov/pubmed/33953993 http://dx.doi.org/10.1155/2021/6623706 |
Ejemplares similares
-
New somatic BRAF splicing mutation in Langerhans cell histiocytosis
por: Héritier, Sébastien, et al.
Publicado: (2017) -
Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia
por: Holst, Johanne Marie, et al.
Publicado: (2021) -
Tumor-Tissue Expression of the Hyaluronic Acid Receptor RHAMM Predicts Histological Transformation in Follicular Lymphoma Patients
por: Enemark, Marie Beck, et al.
Publicado: (2022) -
PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation
por: Beck Enemark, Marie, et al.
Publicado: (2021) -
BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay
por: Tatsuno, Michiko, et al.
Publicado: (2016)